Evidence-based role of bevacizumab in non-small cell lung cancer
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/24/1/6/5644145/mds608.pdf
Reference29 articles.
1. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage non-small cell lung cancer;Scagliotti;J Clin Oncol,2008
2. Maintenance chemotherapy for advanced non-small cell lung cancer: new life for an old idea;Gerber;J Clin Oncol,2013
3. Treating patients with EGFR sensitizing mutations: first line or second line—is there a difference?;Mok;J Clin Oncol,2013
4. Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data form the phase 3 FLEX study;O'Byrne;Lancet Oncol,2011
5. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099;Lynch;J Clin Oncol,2012
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis;Journal for ImmunoTherapy of Cancer;2022-04
2. The expression of vascular endothelial growth factor (VEGF)/ endostatin (ES) and VEGF receptor 2 (VEGFR2)/ES is associated with NSCLC prognosis*;Oncology and Translational Medicine;2021-08
3. Novel EXO-T vaccine using polyclonal CD4+ T cells armed with HER2-specific exosomes for HER2-positive breast cancer;OncoTargets and Therapy;2018-10
4. Immunotherapy in Lung Cancer: A New Age in Cancer Treatment;Advances in Experimental Medicine and Biology;2018
5. Effectiveness outcomes and health related quality of life impact of disease progression in patients with advanced nonsquamous NSCLC treated in real-world community oncology settings: results from a prospective medical record registry study;Health and Quality of Life Outcomes;2017-08-14
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3